Long-Term Debt: ALX Oncology Holdings (ALXO)

Brandmark of ALX Oncology Holdings Inc. (ALXO)

The share price history of ALX Oncology Holdings (ALXO) is independent of economic cycles, relying instead on trial results, with the indicator standing at 0.01. ALX Oncology Holdings (ALXO) is developing safe tumor-fighting methods via CD47 blockade, establishing its authority in oncology. However, significant cash burn and past trial failures pose a liquidity threat and undermine shareholder confidence in the platform's success.

ALXO (ALX Oncology) Company Long-Term Debt history from 07/04/2022 to 11/01/2026

ALX Oncology - analytical breakdowns and key metrics (ALXO)

- current quotes and average value forecast:
Stock Quotes alxoncology.com|ALXO - Price Target Chart
- company stock exchange capitalization indicators:
Market Value ALX Oncology|ALXO - Total Company Value
- book capitalization data:
Net Assets per Single Share ALX Oncology|ALXO - Company Book Value|Market-to-Book Ratio alxoncology.com|ALXO - Company Total Assets
- debt level and financial liquidity data:
Debt to Capital Ratio ALX Oncology Holdings|ALXO - Long-Term Debt to Equity Ratio|Current Liabilities to Capital ALX Oncology Holdings Inc.|ALXO - Company Total Debt|Debt to Net Assets Ratio ALX Oncology|ALXO - Company Long-Term Debts|Short-Term Debt Volume ALX Oncology|Quick Liquidity Indicator alxoncology.com
- net income and valuation multiples indicators:
ALXO - Company Net Income
Fundamental company valuation:alxoncology.com
Core merchandise of ALX Oncology

The use of external CDMO partners to scale protein production minimizes capital expenditures, which directly impacts the liability structure of ALX Oncology Holdings (ALXO). By analyzing the company's current level of long-term debt, an investor assesses the volume of loans with maturities exceeding one year to determine the business's ability to attract debt capital for growth without risking an excessive debt load.

Who ALX Oncology Holdings competes with

IBRX - Company Long-Term Liabilities|IMCR - Company Long-Term Debt|Long-Term Debt Janux Therapeutics Inc|Arcus Bio (RCUS) - Company Long-Term Debt|ZYME (Zymeworks Biopharmaceuticals) - Company Long-Term Debt|Company Long-Term Debt Tango Therapeutics|Long-Term Debt iovance.com IOVA|Company Long-Term Debts IMTX|Xencor Inc (XNCR) - Long-Term Indebtedness|Compass Bio - Company Long-Term Liabilities|Replimune Inc. (REPL) - Long-Term Debt|LYEL: Company Long-Term Liabilities|Company Long-Term Loans and Borrowings IPHA (innate-pharma.com)|PYXS: Company Long-Term Debts|CGEN - Long-Term Debt Volume|Company Long-Term Debt IO Biotech Corp|Company Long-Term Liabilities Sutro Biopharma, Inc (STRO)|Company Long-Term Debt MiNK Therapeutics, Inc. (INKT)|Company Long-Term Liabilities werewolftx.com HOWL|Immix Biopharma - Company Long-Term Liabilities|Company Long-Term Debts cuebiopharma.com CUE|PDSB - Company Long-Term Debt|SONN (Sonnet BioTherapeutics) - Company Long-Term Indebtedness|MAIA Biotechnology (MAIA) - Company Long-Term Debt|Long-Term Debt liminatuspharma.com (LIMN)|Company Long-Term Liabilities LVTX|NXTC - Long-Term Indebtedness|Company Long-Term Liabilities LPTX (Leap Therapeutics, Inc.)|Amount of Long-Term Liabilities INTS|Company Long-Term Debts SNSE (Sensei Biotherapeutics, Inc.)|Company Long-Term Loans and Borrowings TOVX|Gritstone Bio - Company Long-Term Debts|Long-Term Debt Kineta Inc|NexImmune Corp (NEXI) - Company Long-Term Debt|Turnstone Biologics Corp. - Company Long-Term Loans and Borrowings|VCNX (Vaccinex, Inc.) - Company Long-Term Debts|Company Long-Term Debts harpoontx.com